ReviewJournal of neural transmission (Vienna, Austria : 1996)2026
MicroRNAs as biomarkers and molecular mediators of cognitive dysfunction in schizophrenia.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Increased RHOA expression in peripheral blood mononuclear cells of patients with acute schizophrenia.Molecular biology reports · 2026Article
- Article
- Silent regulators of trauma: the microRNA blueprint underlying post-traumatic stress disorder biology.Environmental epigenetics · 2026Review
- From synapse to system: mechanistic pathways of neural signaling dysfunction in psychiatric disorders.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a chronic psychiatric disorder characterized by positive, negative, and cognitive symptoms that impair daily functioning. Among these, cognitive dysfunction, affecting memory, attention, and executive function, is a core feature that lacks effective treatment. The clinical diagnosis of schizophrenia is contingent upon the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), which is based on symptom assessment. However, DSM-5 criteria are subjective and lack biological specificity, leading to diagnostic delays and heterogeneity in patient classification. Emerging evidence implies that microRNAs (miRNAs), small non-coding RNAs that regulate gene expression post-transcriptionally, are integral to the molecular pathways contributing to cognitive dysfunction in schizophrenia. Dysregulated miRNAs impact neurodevelopment, synaptic plasticity, and neurotransmitter signaling, key processes implicated in cognitive impairment. Notably, miRNAs can be found in peripheral biofluids, making them promising non-invasive biomarkers for schizophrenia. Their potential diagnostic utility could enhance early detection and classification, overcoming the limitations of symptom-based clinical assessment. This review discusses the function of dysregulated miRNAs in schizophrenia-associated cognitive deficits, their molecular mechanisms, and their implications as biomarkers. Understanding miRNA-mediated regulation of cognitive function could open the door for innovative diagnostic tools and personalized interventions, ultimately improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.